345 related articles for article (PubMed ID: 26963025)
21. Accumulation of BRI2-BRICHOS ectodomain correlates with a decreased clearance of Aβ by insulin degrading enzyme (IDE) in Alzheimer's disease.
Del Campo M; Stargardt A; Veerhuis R; Reits E; Teunissen CE
Neurosci Lett; 2015 Mar; 589():47-51. PubMed ID: 25597881
[TBL] [Abstract][Full Text] [Related]
22. Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention.
Zhao L; Teter B; Morihara T; Lim GP; Ambegaokar SS; Ubeda OJ; Frautschy SA; Cole GM
J Neurosci; 2004 Dec; 24(49):11120-6. PubMed ID: 15590928
[TBL] [Abstract][Full Text] [Related]
23. Leptin inhibits amyloid β-protein degradation through decrease of neprilysin expression in primary cultured astrocytes.
Yamamoto N; Tanida M; Ono Y; Kasahara R; Fujii Y; Ohora K; Suzuki K; Sobue K
Biochem Biophys Res Commun; 2014 Feb; 445(1):214-7. PubMed ID: 24508800
[TBL] [Abstract][Full Text] [Related]
24. Reduced amyloid-β degradation in early Alzheimer's disease but not in the APPswePS1dE9 and 3xTg-AD mouse models.
Stargardt A; Gillis J; Kamphuis W; Wiemhoefer A; Kooijman L; Raspe M; Benckhuijsen W; Drijfhout JW; Hol EM; Reits E
Aging Cell; 2013 Jun; 12(3):499-507. PubMed ID: 23534431
[TBL] [Abstract][Full Text] [Related]
25. Eicosapentaenoic acid and docosahexaenoic acid increase the degradation of amyloid-β by affecting insulin-degrading enzyme.
Grimm MO; Mett J; Stahlmann CP; Haupenthal VJ; Blümel T; Stötzel H; Grimm HS; Hartmann T
Biochem Cell Biol; 2016 Dec; 94(6):534-542. PubMed ID: 27813426
[TBL] [Abstract][Full Text] [Related]
26. Thrombospondin-1 prevents amyloid beta-mediated synaptic pathology in Alzheimer's disease.
Son SM; Nam DW; Cha MY; Kim KH; Byun J; Ryu H; Mook-Jung I
Neurobiol Aging; 2015 Dec; 36(12):3214-3227. PubMed ID: 26452999
[TBL] [Abstract][Full Text] [Related]
27. The participation of insulin-like growth factor-binding protein 3 released by astrocytes in the pathology of Alzheimer's disease.
Watanabe K; Uemura K; Asada M; Maesako M; Akiyama H; Shimohama S; Takahashi R; Kinoshita A
Mol Brain; 2015 Dec; 8(1):82. PubMed ID: 26637371
[TBL] [Abstract][Full Text] [Related]
28. Calcium-sensing receptor antagonist (calcilytic) NPS 2143 specifically blocks the increased secretion of endogenous Aβ42 prompted by exogenous fibrillary or soluble Aβ25-35 in human cortical astrocytes and neurons-therapeutic relevance to Alzheimer's disease.
Armato U; Chiarini A; Chakravarthy B; Chioffi F; Pacchiana R; Colarusso E; Whitfield JF; Dal Prà I
Biochim Biophys Acta; 2013 Oct; 1832(10):1634-52. PubMed ID: 23628734
[TBL] [Abstract][Full Text] [Related]
29. Clearance of β-amyloid mediated by autophagy is enhanced by MTORC1 inhibition but not AMPK activation in APP/PSEN1 astrocytes.
García-Juan M; Ordóñez-Gutiérrez L; Wandosell F
Glia; 2024 Mar; 72(3):588-606. PubMed ID: 38009275
[TBL] [Abstract][Full Text] [Related]
30. Insulin-degrading enzyme is not secreted from cultured cells.
Song ES; Rodgers DW; Hersh LB
Sci Rep; 2018 Feb; 8(1):2335. PubMed ID: 29402917
[TBL] [Abstract][Full Text] [Related]
31. Autophagy-dependent secretion: mechanism, factors secreted, and disease implications.
New J; Thomas SM
Autophagy; 2019 Oct; 15(10):1682-1693. PubMed ID: 30894055
[TBL] [Abstract][Full Text] [Related]
32. Protein kinases A and C regulate amyloid-β degradation by modulating protein levels of neprilysin and insulin-degrading enzyme in astrocytes.
Yamamoto N; Nakazawa M; Nunono N; Yoshida N; Obuchi A; Tanida M; Suzuki K; Ikeda-Matsuo Y; Sobue K
Neurosci Res; 2021 May; 166():62-72. PubMed ID: 32512031
[TBL] [Abstract][Full Text] [Related]
33. Autophagy-Mediated Secretory Pathway is Responsible for Both Normal and Pathological Tau in Neurons.
Kang S; Son SM; Baik SH; Yang J; Mook-Jung I
J Alzheimers Dis; 2019; 70(3):667-680. PubMed ID: 31256134
[TBL] [Abstract][Full Text] [Related]
34. CALHM1 ion channel elicits amyloid-β clearance by insulin-degrading enzyme in cell lines and in vivo in the mouse brain.
Vingtdeux V; Chandakkar P; Zhao H; Blanc L; Ruiz S; Marambaud P
J Cell Sci; 2015 Jul; 128(13):2330-8. PubMed ID: 25999473
[TBL] [Abstract][Full Text] [Related]
35. Targeting Insulin-Degrading Enzyme to Treat Type 2 Diabetes Mellitus.
Tang WJ
Trends Endocrinol Metab; 2016 Jan; 27(1):24-34. PubMed ID: 26651592
[TBL] [Abstract][Full Text] [Related]
36. Cysteine proteases are the major beta-secretase in the regulated secretory pathway that provides most of the beta-amyloid in Alzheimer's disease: role of BACE 1 in the constitutive secretory pathway.
Hook VY; Reisine TD
J Neurosci Res; 2003 Nov; 74(3):393-405. PubMed ID: 14598316
[TBL] [Abstract][Full Text] [Related]
37. CART modulates beta-amyloid metabolism-associated enzymes and attenuates memory deficits in APP/PS1 mice.
Yin K; Jin J; Zhu X; Yu L; Wang S; Qian L; Han L; Xu Y
Neurol Res; 2017 Oct; 39(10):885-894. PubMed ID: 28743230
[TBL] [Abstract][Full Text] [Related]
38. Insulin-degrading enzyme is exported via an unconventional protein secretion pathway.
Zhao J; Li L; Leissring MA
Mol Neurodegener; 2009 Jan; 4():4. PubMed ID: 19144176
[TBL] [Abstract][Full Text] [Related]
39. Geniposide attenuates insulin-deficiency-induced acceleration of β-amyloidosis in an APP/PS1 transgenic model of Alzheimer's disease.
Zhang Y; Yin F; Liu J; Liu Z; Guo L; Xia Z; Zidichouski J
Neurochem Int; 2015 Oct; 89():7-16. PubMed ID: 25882165
[TBL] [Abstract][Full Text] [Related]
40. Ketamine reduces amyloid β-protein degradation by suppressing neprilysin expression in primary cultured astrocytes.
Yamamoto N; Arima H; Naruse K; Kasahara R; Taniura H; Hirate H; Sugiura T; Suzuki K; Sobue K
Neurosci Lett; 2013 Jun; 545():54-8. PubMed ID: 23624023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
